An ISRCTN Awarded for Reparagen by Controlled Clinical Trials

Controlled clinical trials (CCT), an international agency that reviews randomized clinical trials, has reviewed the current clinical trial for Reparagen in the treatment of moderate osteoarthritis of the knee. The trial is designed and executed by the contract research organization, Santerra Pharmaceuticals (http://www.santerra-pharma.com/) and compares Reparagen with Glucosamine. The details of the clinical trial can be viewed at the CCT website (http://www.controlled-trials.com/ISRCTN25438351). Park Labs is very pleased with the third party validation of the research protocol and the awarding of an ISRCTN. This review process and validation sets exemplary standards not only for the product, but also for the research that validates the actions, applications and safety of Reparagen.